CA3220929A1 - Fused tetracyclic compound, preparation method therefor and application thereof in medicine - Google Patents
Fused tetracyclic compound, preparation method therefor and application thereof in medicine Download PDFInfo
- Publication number
- CA3220929A1 CA3220929A1 CA3220929A CA3220929A CA3220929A1 CA 3220929 A1 CA3220929 A1 CA 3220929A1 CA 3220929 A CA3220929 A CA 3220929A CA 3220929 A CA3220929 A CA 3220929A CA 3220929 A1 CA3220929 A1 CA 3220929A1
- Authority
- CA
- Canada
- Prior art keywords
- omom
- boc
- fluoro
- hexahydro
- methanonaphtho
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110687643 | 2021-06-21 | ||
| CN202110687643.8 | 2021-06-21 | ||
| CN202110880105 | 2021-08-02 | ||
| CN202110880105.0 | 2021-08-02 | ||
| CN202111073775 | 2021-09-14 | ||
| CN202111073775.8 | 2021-09-14 | ||
| CN202111225928.6 | 2021-10-21 | ||
| CN202111225928 | 2021-10-21 | ||
| PCT/CN2022/100016 WO2022268051A1 (zh) | 2021-06-21 | 2022-06-21 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3220929A1 true CA3220929A1 (en) | 2022-12-29 |
Family
ID=84544976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220929A Pending CA3220929A1 (en) | 2021-06-21 | 2022-06-21 | Fused tetracyclic compound, preparation method therefor and application thereof in medicine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240327434A1 (https=) |
| EP (1) | EP4361157A4 (https=) |
| JP (1) | JP2024522766A (https=) |
| KR (1) | KR20240024903A (https=) |
| CN (1) | CN117255793A (https=) |
| AU (1) | AU2022297474A1 (https=) |
| BR (1) | BR112023024646A2 (https=) |
| CA (1) | CA3220929A1 (https=) |
| MX (1) | MX2023015533A (https=) |
| TW (1) | TW202317587A (https=) |
| WO (1) | WO2022268051A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| CA3211725A1 (en) * | 2021-03-17 | 2022-09-22 | Tao Jiang | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| AU2022303440A1 (en) * | 2021-07-02 | 2024-02-22 | Shanghai De Novo Pharmatech Co., Ltd. | Kras g12d inhibitor and use thereof |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| US20250034166A1 (en) * | 2021-09-27 | 2025-01-30 | Jacobio Pharmaceuticals Co., Ltd. | Polycyclic fused ring derivatives and use thereof |
| EP4471037A1 (en) * | 2022-01-30 | 2024-12-04 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinoline compound and use thereof |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| CR20240508A (es) * | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| CN119790058A (zh) * | 2022-07-09 | 2025-04-08 | 荣山医药股份有限公司 | 用于治疗疾病的稠合环kras抑制剂 |
| WO2024022444A1 (zh) * | 2022-07-27 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| AU2023314335A1 (en) * | 2022-07-29 | 2025-02-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising kras g12d inhibitor |
| CN119585278A (zh) * | 2022-08-05 | 2025-03-07 | 杭州中美华东制药有限公司 | 具有KRas G12D抑制作用的化合物 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| AU2023388747A1 (en) * | 2022-12-07 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused cyclic compounds and use thereof |
| EP4640689A1 (en) * | 2022-12-20 | 2025-10-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of kras g12d inhibitor and preparation method therefor |
| WO2024149214A1 (en) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2024234360A1 (en) * | 2023-05-18 | 2024-11-21 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024159471A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| EP4695262A1 (en) * | 2023-04-10 | 2026-02-18 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| AU2024306338A1 (en) * | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121399088A (zh) | 2023-07-13 | 2026-01-23 | 上海森辉医药有限公司 | Kras g12d中间体的制备方法 |
| TW202517649A (zh) * | 2023-07-18 | 2025-05-01 | 大陸商泰勵生物科技（上海）有限公司 | 具有抗ｋｒａｓ突變腫瘤活性的化合物 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024374420A1 (en) * | 2023-11-02 | 2026-04-16 | Kumquat Biosciences Inc. | Degraders and uses thereof |
| WO2025108443A2 (en) * | 2023-11-23 | 2025-05-30 | Beigene Switzerland Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| WO2025153038A1 (en) * | 2024-01-17 | 2025-07-24 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| CN119684315A (zh) * | 2024-01-26 | 2025-03-25 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025157261A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物晶型及其制备方法 |
| CN119661556B (zh) * | 2024-01-26 | 2025-12-09 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| CN119490512A (zh) * | 2024-01-26 | 2025-02-21 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| TW202110837A (zh) | 2019-05-24 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021000885A1 (zh) * | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CA3211725A1 (en) * | 2021-03-17 | 2022-09-22 | Tao Jiang | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| WO2022199587A1 (zh) * | 2021-03-24 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| CN116113632B (zh) * | 2021-03-30 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| AU2022303440A1 (en) * | 2021-07-02 | 2024-02-22 | Shanghai De Novo Pharmatech Co., Ltd. | Kras g12d inhibitor and use thereof |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| CN116323625A (zh) * | 2021-08-25 | 2023-06-23 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| EP4471037A1 (en) * | 2022-01-30 | 2024-12-04 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinoline compound and use thereof |
| CR20240451A (es) * | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| CR20240508A (es) * | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
-
2022
- 2022-06-21 EP EP22827544.2A patent/EP4361157A4/en active Pending
- 2022-06-21 TW TW111123050A patent/TW202317587A/zh unknown
- 2022-06-21 JP JP2023577689A patent/JP2024522766A/ja active Pending
- 2022-06-21 MX MX2023015533A patent/MX2023015533A/es unknown
- 2022-06-21 US US18/571,909 patent/US20240327434A1/en active Pending
- 2022-06-21 BR BR112023024646A patent/BR112023024646A2/pt unknown
- 2022-06-21 CA CA3220929A patent/CA3220929A1/en active Pending
- 2022-06-21 KR KR1020247000906A patent/KR20240024903A/ko active Pending
- 2022-06-21 AU AU2022297474A patent/AU2022297474A1/en active Pending
- 2022-06-21 CN CN202280030759.7A patent/CN117255793A/zh active Pending
- 2022-06-21 WO PCT/CN2022/100016 patent/WO2022268051A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4361157A4 (en) | 2024-10-16 |
| CN117255793A (zh) | 2023-12-19 |
| AU2022297474A1 (en) | 2024-01-18 |
| BR112023024646A2 (pt) | 2024-03-05 |
| KR20240024903A (ko) | 2024-02-26 |
| US20240327434A1 (en) | 2024-10-03 |
| WO2022268051A1 (zh) | 2022-12-29 |
| MX2023015533A (es) | 2024-01-23 |
| TW202317587A (zh) | 2023-05-01 |
| JP2024522766A (ja) | 2024-06-21 |
| EP4361157A1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3220929A1 (en) | Fused tetracyclic compound, preparation method therefor and application thereof in medicine | |
| EP4563580A1 (en) | Fused ring compound, preparation method therefor and medicinal application thereof | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| ES2857251T3 (es) | Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton | |
| TW202409047A (zh) | 吡啶并［４，３－ｄ］嘧啶化合物 | |
| CN117486901A (zh) | 稠合哌啶类化合物、其制备方法及其在医药上的应用 | |
| ES2896943T3 (es) | Compuesto de amino pirazolopirimidina usado como inhibidor de receptores con actividad tirosina quinasa de factores neurotróficos | |
| WO2024213979A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| CA3120791A1 (en) | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof | |
| CA3180615A1 (en) | Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof | |
| UA119229C2 (uk) | Циклічні ефіри піразол-4-ілгетероциклілкарбоксамідних сполук та способи їх застосування | |
| CA3232764A1 (en) | Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof | |
| CN112824410A (zh) | 氮杂七元环类抑制剂及其制备方法和应用 | |
| KR20240012437A (ko) | 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용 | |
| CA3159376A1 (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| AU2021314401A1 (en) | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof | |
| CN120365289A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| CN114907349A (zh) | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 | |
| JP6554480B2 (ja) | オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 | |
| CN117659049A (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| CN113912608A (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| JP2026059772A (ja) | ピリド［４，３－ｄ］ピリミジン化合物 | |
| KR20260044145A (ko) | 피리도[4,3-d]피리미딘 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |